Persistent disease and recurrence in differentiated thyroid cancer patients with undetectable postoperative stimulated thyroglobulin level.
about
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid CancerEffects of low-dose and high-dose postoperative radioiodine therapy on the clinical outcome in patients with small differentiated thyroid cancer having microscopic extrathyroidal extension.Diagnostic Performance of 18F-FDG PET/CT in Papillary Thyroid Carcinoma with Negative 131I-WBS at first Postablation, Negative Tg and Progressively Increased TgAb Level.Ability of the rhTSH stimulation test to predict relapse in patients with differentiated thyroid carcinoma, after long-term follow-up.The Delayed Risk Stratification System in the Risk of Differentiated Thyroid Cancer Recurrence.Long-term clinical outcome of differentiated thyroid cancer patients with undetectable stimulated thyroglobulin level one year after initial treatmentImpact of prophylactic central neck dissection on oncologic outcomes of papillary thyroid carcinoma: a review.Clinical analysis of prophylactic central neck dissection for papillary thyroid carcinomaRisk factors associated with high thyroglobulin level following radioactive iodine ablation, measured 12 months after treatment for papillary thyroid carcinoma.Preablation Stimulated Thyroglobulin/TSH Ratio as a Predictor of Successful I(131)Remnant Ablation in Patients with Differentiated Thyroid Cancer following Total Thyroidectomy.2013 European thyroid association guidelines for cervical ultrasound scan and ultrasound-guided techniques in the postoperative management of patients with thyroid cancer.Prospective Study Confirms that Radioiodine Remnant Ablation Is Not Necessary in Low-Risk Differentiated Thyroid Cancer.2016 Chinese expert consensus and guidelines for the diagnosis and treatment of papillary thyroid microcarcinoma
P2860
Q30367068-24E18604-2F53-4D17-85B5-BA9914E04AD9Q33632648-A9237B5E-4AEB-4ED0-96ED-2465D7FA0FD0Q33767437-EB81A4E2-26D2-4000-BA01-0BF807110ED7Q35042089-FE7DB937-E03B-4BE7-BC4B-02C07442E88BQ35989876-4F26691E-9609-4203-BC98-F9009D31E2ABQ36124278-D529DD02-08AD-46EC-8265-0E7FAF308B0DQ37178936-1DBDF1C8-DEF8-4A19-A321-6914C5976A0DQ37446775-3110923C-A61F-4C8B-82F9-07CD2E3CB0F6Q37585292-C83F474A-EBBA-45F8-8128-53B54B24018CQ37724978-B17B883B-5A69-41C8-9A8C-C35BB510B8C8Q38213399-CE426683-00D3-4057-B446-98A076D575C9Q40330011-70D637FF-DC24-4647-AAE6-362783820487Q41514177-918B1870-F2FC-482F-B48C-8E9CAFBA44B1
P2860
Persistent disease and recurrence in differentiated thyroid cancer patients with undetectable postoperative stimulated thyroglobulin level.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 March 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Persistent disease and recurre ...... timulated thyroglobulin level.
@en
Persistent disease and recurre ...... timulated thyroglobulin level.
@nl
type
label
Persistent disease and recurre ...... timulated thyroglobulin level.
@en
Persistent disease and recurre ...... timulated thyroglobulin level.
@nl
prefLabel
Persistent disease and recurre ...... timulated thyroglobulin level.
@en
Persistent disease and recurre ...... timulated thyroglobulin level.
@nl
P2093
P356
P1476
Persistent disease and recurre ...... stimulated thyroglobulin level
@en
P2093
A Al Ghuzlan
C Chougnet
C Nascimento
D Deandreis
J Lumbroso
J P Travagli
P304
P356
10.1677/ERC-10-0292
P577
2011-03-03T00:00:00Z